Gene panel test is a genetic testing tool which sequences the whole genome of the patient suspected to be suffering from diseases caused due to genetic mutations or are genetically inherited such as cancer, cardiovascular diseases, and others. Few applications of gene panel include pharmacogenetics, diagnosis of congenital disorders, and for cancer risk assessment. Gene panel is an important diagnostic tool for early detection and prediction of rare genetic mutations that cause diseases such as Lynch Syndrome (hereditary non-polyposis colorectal cancer) as it puts people at higher risk than other types of cancers such as stomach, ovarian, and colon. Targeted gene panels can be used for analysis of specific gene mutation associated with the disease or associated with the phenotypic characteristic that is under study/research. Recent advances in the field of gene sequencing has led to the development of customized gene panels as required by the user.
Global Gene Panel Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020.
According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 186,240,393 cases and 4,027,861 deaths due to coronavirus disease (COVID-19) were reported till July 11, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Gene Panel
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the biotechnology industry mainly due to strict lockdown in several regions. The coronavirus pandemic has impacted development, production, and supply of healthcare products and affected businesses of various companies operating in the healthcare sector across the globe. The pandemic has led to the closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of healthcare products.
However, the rising incidences of cardiovascular diseases, arthritis, and neurological diseases associated with COVID-19 infection are expected to have a positive impact on the market growth of gene panel, as gene panels can be used for the detection of such diseases. For instance, according to an article published by the JAMA Cardiology Journal in July 2020, a gene panel consisting of six pro-inflammatory genes was used to show that the activity of these genes was higher in heart of COVID-19 patients as compared to the COVID-19 negative population. According to an article published by the National Centers for Biotechnology Information in January 2021, a study conducted in Wuhan, China, revealed that out of 221 COVID-19 positive patients, approximately 5% had ischemic stroke and 0.5% had hemorrhagic stroke. In another study from the same region, out of 214 COVID-19 positive patients, about 5.7% people with severe COVID infection were reported with acute cerebrovascular disease.
Thus, impact of the coronavirus (COVID-19) pandemic is expected to aid the growth of the global gene panel market during the forecast period, owing to the need for reliable gene panels as a diagnostic tool for detection of comorbid diseases associated with COVID-19 infection.
The global gene panel market is estimated to be valued at US$ 22,044.7 Mn in 2021, and is expected to exhibit a CAGR of 20.2% over the forecast period (2021-2028).
|Base Year:||2020||Market Size in 2021:||US$ 22,044.7 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||20.2%||2028 Value Projection:||US$ 29,975.8 Mn|
Thermo Fisher Scientific Inc., BGI, GENEWIZ, Inc., GATC Biotech, Novogene Co., Ltd., QIAGEN, Integrated DNA Technologies, Inc., Illumina Inc., Agilent Technologies, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Personalis Inc., GeneDx Inc., and Invitae Corporation.
|Restraints & Challenges:||
Figure 1: Global Gene Panel Market Share (%) Analysis, By Technique, 2021
The increasing burden of chronic diseases is the major factor that is expected to drive the market growth of gene panel over the forecast period.
The rising burden of chronic diseases which are associated with genes such as stroke, heart attack, cancer, arthritis, and others are expected to drive growth of gene panel market over the forecast period. According to the data provided by the International Agency for Research on Cancer (IRAC) in 2018, it is estimated that there will be more than 27.5 million new cancer cases by 2040, which would be majorly due to factors such as unhealthy lifestyle, smoking, and reduced physical activities. Also, according to the statistics provided by the World Health Organization in 2018, over 795,000 people have stroke each year in the U.S. This is expected to create opportunities for gene panel market as a clinical diagnostic tool.
The rising number of product launch and approval is expected to drive the growth of the global gene panel market over the forecast period. For instance, in September 2020, Bionano Genomics, an American genomic diagnostics manufacturer, announced the launch of EpiPanelDx PLUS, which is a gene panel test for diagnosis of epilepsy.
Global Gene Panel Market – Restraints
However, growth of the gene panel market may be hampered, owing to inability of next generation sequencing (NGS) gene panels in detecting some allelic mutations. According to an article published by the Scientific Electronic Library Online in 2019, NGS based gene panels were found to be inefficient in detecting some allelic mutations associated with lysosomal storage disorders (LSD).
Global Gene Panel Market – Regional Analysis
On the basis of region, the global gene panel market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global gene panel market over the forecast period, owing to rising collaborations and partnerships between market players. For instance, in October 2019, Illumina, Inc., an American biotechnology company, and QIAGEN, a German molecular diagnostic company, announced a 15-year partnership to boost the distribution of next generation sequencing-based diagnostic kits to be used in conducting gene panels.
Figure 2: Global Gene Panel Market Value (US$ 8,773.8 Mn), by Region, 2021
Global Gene Panel Market – Competitive Landscape
Major players operating in the global gene panel market include Thermo Fisher Scientific Inc., BGI, GENEWIZ, Inc., GATC Biotech, Novogene Co., Ltd., QIAGEN, Integrated DNA Technologies, Inc., Illumina Inc., Agilent Technologies, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Personalis Inc., GeneDx Inc., and Invitae Corporation
Gene panels are specialized diagnostic tools used to assess multiple genes at once for mutations related to diseases such as cancer, cardiomyopathy, and others. Gene panels enable the users to obtain results at a reduced cost and time. Gene panels are useful in sequencing genes such as BRCA1 to detect mutations that may lead to cancer. DNA sample from blood, muscle or saliva can be used in gene panel testing. Low muscle tone, epilepsy, and short stature are few conditions which can be diagnosed using gene panel tests. Rapid research in DNA sequencing technology has led to the advancement of gene panels making them more efficient, economical, and flexible.
Market players are conducting clinical trials for exploring the potential uses of gene panels for diagnosis of a number of genetic disorders, which could contribute to the growth of the gene panel market over the forecast period. For instance, in November 2020 Bordeaux University Hospital, France, initiated an observational clinical study for implementation of a next generation sequencing gene panel for diagnosis of incomplete forms of albinism. This study identifies the usability of NGS gene panel in overcoming the challenges faced in identification of ocular albinism as it does not show many observable ophthalmic signs. This study comprises of 100 participants and is expected to be completed by March 2022.
Market players are focusing on launch of products, which is expected to strengthen their position in the global gene panel market. For instance, in June 2018, Thermo Fisher Scientific Inc., an American scientific instrumentation company, launched Ion AmpliSeq HD technology as an amplicon-based library for targeted next gene sequencing, it enables the user to customize one’s own gene panel by selecting the appropriate gene sequences from the gene library which are associated with a particular disease and detect low-frequency alleles in tumor RNA or DNA.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.